INNOVENT BIO (01801.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec25

Innovent's TABOSUN® Approved for Colorectal Cancer Treatment

08:45

Innosyne Biologics shareholders deposit stocks into HSBC

00:12

Dec23

Shanghai Market Supervision Administration Enforcement Team Signs Compliance System Construction Cooperation Memorandum with Innovent Biologics

05:48

Dec19

JPMorgan Sees Opportunities in China's Healthcare Sector, Recommends Biotech and CXO Stocks

02:54

Dec15

Innovent Biologics' Masdutide Receives Approval from Macau's Drug Regulatory Authority

07:10

Dec12

Innovent Biologics Announces Success of Mazdutide Phase 1b Clinical Trial and Plans to Initiate Phase 3 Trial

00:00

Schedules & Filings

Schedules

Filings

Aug27

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 3.258 B, Net Income 456.59 M, EPS 0.2681

Mar26

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 2.909 B, Net Income 158.51 M, EPS 0.0951

Aug28

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 2.123 B, Net Income -210.94 M, EPS -0.1299

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change